The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Cannabidiol for the Reduction of Cue-Induced Craving and Anxiety in Drug-Abstinent Individuals With Heroin Use Disorder: A Double-Blind Randomized Placebo-Controlled Trial
Abstract
OBJECTIVE: Despite the staggering consequences of the opioid epidemic, limited nonopioid medication options have been developed to treat this medical and public health crisis. This study investigated the potential of cannabidiol (CBD), a nonintoxicating phytocannabinoid, to reduce cue-induced craving and anxiety, two critical features of addiction that often contribute to relapse and continued drug use, in drug-abstinent individuals with heroin use disorder. METHODS: This exploratory double-blind randomized placebo-controlled trial assessed the acute (1 hour, 2 hours, and 24 hours), short-term (3 consecutive days), and protracted (7 days after the last of three consecutive daily administrations) effects of CBD administration (400 or 800 mg, once daily for 3 consecutive days) on drug cue-induced craving and anxiety in drug-abstinent individuals with heroin use disorder. Secondary measures assessed participants' positive and negative affect, cognition, and physiological status. RESULTS: Acute CBD administration, in contrast to placebo, significantly reduced both craving and anxiety induced by the presentation of salient drug cues compared with neutral cues. CBD also showed significant protracted effects on these measures 7 days after the final short-term (3-day) CBD exposure. In addition, CBD reduced the drug cue-induced physiological measures of heart rate and salivary cortisol levels. There were no significant effects on cognition, and there were no serious adverse effects. CONCLUSIONS: CBD's potential to reduce cue-induced craving and anxiety provides a strong basis for further investigation of this phytocannabinoid as a treatment option for opioid use disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Bergamaschi, M. M., Queiroz, R. H. C., Chagas, M. H. N., de Oliveira, D. C. G., De Martinis, B. S., Kapczinski, F., Quevedo, J., Roesler, R., Schröder, N., Nardi, A. E., et al. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.6 · Cited by 771 · cited 2×
“In addition, CBD has been shown to reduce anxiety (20, 21), which we expected to be enhanced by the presentation of drug cues (22).”
Iffland, K., & Grotenhermen, F. (2017) · Cannabis & Cannabinoid Research · doi:10.1089/can.2016.0034 · Cited by 645
Safety and side effects of cannabidiol, a Cannabis sativa constituent
Machado Bergamaschi, M., Helena Costa Queiroz, R., Waldo Zuardi, A., & Alexandre S. Crippa, J. (2011) · Current Drug Safety · doi:10.2174/157488611798280924 · Cited by 558 · cited 1×
“Consistent with previous reports (27, 28), no serious adverse events were noted in association with CBD administration throughout the duration of the trial.”
Crippa, J. A. S., Derenusson, G. N., Ferrari, T. B., Wichert-Ana, L., Duran, F. L., Martin-Santos, R., Simões, M. V., Bhattacharyya, S., Fusar-Poli, P., Atakan, Z., et al. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110379283 · Cited by 535
Fusar-Poli, P., Crippa, J. A., Bhattacharyya, S., Borgwardt, S. J., Allen, P., Martin-Santos, R., Seal, M., Surguladze, S. A., O’Carrol, C., Atakan, Z., et al. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2008.519 · Cited by 465
Antianxiety effect of cannabidiol in the elevated plus-maze
Guimarães, F. S., Chiaretti, T. M., Graeff, F. G., & Zuardi, A. W. (1990) · Psychopharmacology · doi:10.1007/bf02244012 · Cited by 379 · cited 1×
“The results of numerous animal models have also reinforced the anxiolytic role of CBD (34, 35).”
Effects of ipsapirone and cannabidiol on human experimental anxiety
Zuardi, A. W., Cosme, R. A., Graeff, F. G., & Guimarães, F. S. (1993) · Journal of Psychopharmacology · doi:10.1177/026988119300700112 · Cited by 364
Ren, Y., Whittard, J., Higuera-Matas, A., Morris, C. V., & Hurd, Y. L. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.4291-09.2009 · Cited by 210
Self-citationBhattacharyya, S. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.161 · Cited by 203
Research works printed but not linked: 22
- 10.1097/ADM.0000000000000412 · doi:10.1097/adm.0000000000000412
- 10.3949/ccjm.84a.16091 · DOI
- 10.1007/s11920-017-0783-9 · DOI · Paper page
- 10.2105/AJPH.2015.302664 · DOI · Paper page
- 10.1016/j.drugalcdep.2016.10.015 · DOI · Paper page
- 10.1097/ADM.0000000000000118 · DOI
- 10.1007/s13311-015-0373-7 · DOI · Paper page
- 10.1016/j.drugalcdep.2016.11.030 · DOI
- 10.1111/adb.12495 · DOI
- 10.1007/s40263-018-0578-5 · DOI · Paper page
- 10.1111/bph.12735 · DOI
- 10.1037/1064-1297.15.2.134 · DOI · Paper page
- 10.1111/add.14243 · DOI
- 10.1038/sj.npp.1300340 · DOI · Paper page
- 10.1111/ajad.12344 · DOI · Paper page
- 10.1038/s41386-018-0050-8 · DOI
- 10.1111/j.1360-0443.2006.01498.x · DOI · Paper page
- 10.1016/j.neuropharm.2018.03.001 · DOI · Paper page
- 10.1016/j.biopsych.2013.10.019 · DOI
- 10.1038/s41598-018-25846-2 · DOI
- 10.1089/can.2015.0004 · DOI
- 10.1089/can.2017.0009 · DOI · Paper page
Cited by
Freeman, T. P., Craft, S., Wilson, J., Stylianou, S., ElSohly, M., Di Forti, M., & Lynskey, M. T. (2021) · Addiction · doi:10.1111/add.15253 · Cited by 337
Cannabidiol: pharmacology and therapeutic targets
Britch, S. C., Babalonis, S., & Walsh, S. L. (2021) · Psychopharmacology · doi:10.1007/s00213-020-05712-8 · Cited by 307
García-Gutiérrez, M. S., Navarrete, F., Gasparyan, A., Austrich-Olivares, A., Sala, F., & Manzanares, J. (2020) · Biomolecules · doi:10.3390/biom10111575 · Cited by 306
Bilbao, A., & Spanagel, R. (2022) · BMC Medicine · doi:10.1186/s12916-022-02459-1 · Cited by 181
Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder
Burnette, E. M., Nieto, S. J., Grodin, E. N., Meredith, L. R., Hurley, B., Miotto, K., Gillis, A. J., & Ray, L. A. (2022) · Drugs · doi:10.1007/s40265-021-01670-3 · Cited by 169
Metadata
- Authors
- Hurd, Y. L., Spriggs, S., Alishayev, J., Winkel, G., Gurgov, K., Kudrich, C., Oprescu, A. M., & Salsitz, E.
- Venue
- American Journal of Psychiatry
- Published
- 2019-11-01
- Volume
- 176
- Issue
- 11
- Pages
- 911-922
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2946027664
- Cited by
- 343
- References
- 15
- FWCI
- 24.80
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cannabidiol for the Reduction of Cue-Induced Craving and Anxiety in Drug-Abstinent Individuals With Heroin Use Disorder: A Double-Blind Randomized Placebo-Controlled Trial. https://app.cochat.ai/papers/10.1176/appi.ajp.2019.18101191
- The paper
- Hurd, Y. L., Spriggs, S., Alishayev, J., Winkel, G., Gurgov, K., Kudrich, C., Oprescu, A. M., & Salsitz, E. (2019). Cannabidiol for the Reduction of Cue-Induced Craving and Anxiety in Drug-Abstinent Individuals With Heroin Use Disorder: A Double-Blind Randomized Placebo-Controlled Trial. American Journal of Psychiatry. https://doi.org/10.1176/appi.ajp.2019.18101191
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.